Markus Grabbert

Apr 11, 2024 | europeanurology.com | Markus Grabbert |Christian Gratzke

Fizazi K, Bernard-Tessier A, Roubaud G, et alNEJM Evid 2024;3:EVIDoa2300171[1]Fizazi K. Bernard-Tessier A. Roubaud G. et al. Targeted inhibition of CYP11A1 in castration-resistant prostate cancer. NEJM Evid.

Apr 11, 2024 | europeanurology.com | Markus Grabbert |Christian Gratzke

Fizazi K, Bernard-Tessier A, Roubaud G, et alTo read this article in full you will need to make a paymentSubscribe to European UrologyReferencesTargeted inhibition of CYP11A1 in castration-resistant prostate cancer. NEJM Evid. 3EVIDoa2300171TALAPRO-2: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol.